Big Pharma shills & skeptics of homeopathy indulge in spreading misinformation about homeopathy. This blog aims to set the record straight, and is packed with references to real evidence.
"Homeopaths may not yet adequately understand precisely how their medicines work, but the body of historical and present-day evidence and experience is simply too significant to ignore. "
One could say/state the same about mRNA technology which has been deployed with reckless abandon upon the masses.
The difference between homeopathic medicines vs. mRNA medicines is stunningly clear, one heals/offers solutions and has successfully stood the test of time, while the other has a 'spotty' (I'm being nice) record at best.
PS:
I see you posting over at Dr. Vinay Prasad's recent measles article, "Public health's stupidity will lead to more…".
You mention benefits of (your comment):
"childhood diseases provide important cardiovascular and immunological benefits"
I tried posting but I'm not a paid suscriber.
Worth mentioning the 'oncological' benefits as well of measles.
Measles to the Rescue: A Review of Oncolytic Measles Virus
Abstract
Oncolytic virotherapeutic agents are likely to become serious contenders in cancer treatment. The vaccine strain of measles virus is an agent with an impressive range of oncolytic activity in pre-clinical trials with increasing evidence of safety and efficacy in early clinical trials. This paramyxovirus vaccine has a proven safety record and is amenable to careful genetic modification in the laboratory. Overexpression of the measles virus (MV) receptor CD46 in many tumour cells may direct the virus to preferentially enter transformed cells and there is increasing awareness of the importance of nectin-4 and signaling lymphocytic activation molecule (SLAM) in oncolysis. Successful attempts to retarget MV by inserting genes for tumour-specific ligands to antigens such as carcinoembryonic antigen (CEA), CD20, CD38, and by engineering the virus to express synthetic microRNA targeting sequences, and “blinding” the virus to the natural viral receptors are exciting measures to increase viral specificity and enhance the oncolytic effect. Sodium iodine symporter (NIS) can also be expressed by MV, which enables in vivo tracking of MV infection. Radiovirotherapy using MV-NIS, chemo-virotherapy to convert prodrugs to their toxic metabolites, and immune-virotherapy including incorporating antibodies against immune checkpoint inhibitors can also increase the oncolytic potential. Anti-viral host immune responses are a recognized barrier to the success of MV, and approaches such as transporting MV to the tumour sites by carrier cells, are showing promise. MV Clinical trials are producing encouraging preliminary results in ovarian cancer, myeloma and cutaneous non-Hodgkin lymphoma, and the outcome of currently open trials in glioblastoma multiforme, mesothelioma and squamous cell carcinoma are eagerly anticipated.
I'll keep reading your work and thank you for all you're doing to put sunlight on the disease of Pharma.
Thanx for your comment, Greg...however, are you saying that the measles virus itself provides some protection against cancer OR that a newly modified measles vaccine can be used to prevent or treat someone with cancer?
Measles virus offers an ideal platform from which to build a new generation of safe, effective oncolytic viruses. Occasional "spontaneous" tumor regressions have occurred during natural measles infections, but common tumors do not express SLAM, the wild-type MV receptor, and are therefore not susceptible to the virus. Serendipitously, attenuated vaccine strains of measles virus have adapted to use CD46, a regulator of complement activation that is expressed in higher abundance on human tumor cells than on their non transformed counterparts. For this reason, attenuated measles viruses are potent and selective oncolytic agents showing impressive antitumor activity in mouse xenograft models. The viruses can be engineered to enhance their tumor specificity, increase their antitumor potency and facilitate noninvasive in vivo monitoring of their spread. A major impediment to the successful deployment of oncolytic measles viruses as anticancer agents is the high prevalence of pre-existing anti measles immunity, which impedes bloodstream delivery and curtails intratumoral virus spread. It is hoped that these problems can be addressed by delivering the virus inside measles-infected cell carriers and/or by concomitant administration of immunosuppressive drugs. From a safety perspective, population immunity provides an excellent defense against measles spread from patient to carers and, in fifty years of human experience, reversion of attenuated measles to a wild type pathogenic phenotype has not been observed. Clinical trials testing oncolytic measles viruses as an experimental cancer therapy are currently underway.
Thank you for the research! So hard to explain Homeopathy to new patients. They take it, it works, they come back, want more, still not knowing how it really works! Great stuff. Just gave my puppy a dose of Ledum 200CH after his 2nd booster shots. He stopped trying to nip at the injection site, and fell asleep.
This is a really good summary but I think we focus too much on the hardware of the body and somehow miss its software, the information system of the body. Any plant or animal based medicines has a very complex information mix which is not comparable to metals or other minerals and the body has to be able to "read" these complex info patterns some way or other. So we should start to focus on the software, the information system as well.
Sometimes it does...though no method is 100%...and because many acute symptoms are the results of chronic disease, the Voll machine sometimes is not adequately sensitive to such complexities.
Dana,
Per your quote above:
"Homeopaths may not yet adequately understand precisely how their medicines work, but the body of historical and present-day evidence and experience is simply too significant to ignore. "
One could say/state the same about mRNA technology which has been deployed with reckless abandon upon the masses.
The difference between homeopathic medicines vs. mRNA medicines is stunningly clear, one heals/offers solutions and has successfully stood the test of time, while the other has a 'spotty' (I'm being nice) record at best.
PS:
I see you posting over at Dr. Vinay Prasad's recent measles article, "Public health's stupidity will lead to more…".
You mention benefits of (your comment):
"childhood diseases provide important cardiovascular and immunological benefits"
I tried posting but I'm not a paid suscriber.
Worth mentioning the 'oncological' benefits as well of measles.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5086626/
Measles to the Rescue: A Review of Oncolytic Measles Virus
Abstract
Oncolytic virotherapeutic agents are likely to become serious contenders in cancer treatment. The vaccine strain of measles virus is an agent with an impressive range of oncolytic activity in pre-clinical trials with increasing evidence of safety and efficacy in early clinical trials. This paramyxovirus vaccine has a proven safety record and is amenable to careful genetic modification in the laboratory. Overexpression of the measles virus (MV) receptor CD46 in many tumour cells may direct the virus to preferentially enter transformed cells and there is increasing awareness of the importance of nectin-4 and signaling lymphocytic activation molecule (SLAM) in oncolysis. Successful attempts to retarget MV by inserting genes for tumour-specific ligands to antigens such as carcinoembryonic antigen (CEA), CD20, CD38, and by engineering the virus to express synthetic microRNA targeting sequences, and “blinding” the virus to the natural viral receptors are exciting measures to increase viral specificity and enhance the oncolytic effect. Sodium iodine symporter (NIS) can also be expressed by MV, which enables in vivo tracking of MV infection. Radiovirotherapy using MV-NIS, chemo-virotherapy to convert prodrugs to their toxic metabolites, and immune-virotherapy including incorporating antibodies against immune checkpoint inhibitors can also increase the oncolytic potential. Anti-viral host immune responses are a recognized barrier to the success of MV, and approaches such as transporting MV to the tumour sites by carrier cells, are showing promise. MV Clinical trials are producing encouraging preliminary results in ovarian cancer, myeloma and cutaneous non-Hodgkin lymphoma, and the outcome of currently open trials in glioblastoma multiforme, mesothelioma and squamous cell carcinoma are eagerly anticipated.
I'll keep reading your work and thank you for all you're doing to put sunlight on the disease of Pharma.
Best
Greg
Thanx for your comment, Greg...however, are you saying that the measles virus itself provides some protection against cancer OR that a newly modified measles vaccine can be used to prevent or treat someone with cancer?
Actual measles virus.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3926122/
Abstract
Measles virus offers an ideal platform from which to build a new generation of safe, effective oncolytic viruses. Occasional "spontaneous" tumor regressions have occurred during natural measles infections, but common tumors do not express SLAM, the wild-type MV receptor, and are therefore not susceptible to the virus. Serendipitously, attenuated vaccine strains of measles virus have adapted to use CD46, a regulator of complement activation that is expressed in higher abundance on human tumor cells than on their non transformed counterparts. For this reason, attenuated measles viruses are potent and selective oncolytic agents showing impressive antitumor activity in mouse xenograft models. The viruses can be engineered to enhance their tumor specificity, increase their antitumor potency and facilitate noninvasive in vivo monitoring of their spread. A major impediment to the successful deployment of oncolytic measles viruses as anticancer agents is the high prevalence of pre-existing anti measles immunity, which impedes bloodstream delivery and curtails intratumoral virus spread. It is hoped that these problems can be addressed by delivering the virus inside measles-infected cell carriers and/or by concomitant administration of immunosuppressive drugs. From a safety perspective, population immunity provides an excellent defense against measles spread from patient to carers and, in fifty years of human experience, reversion of attenuated measles to a wild type pathogenic phenotype has not been observed. Clinical trials testing oncolytic measles viruses as an experimental cancer therapy are currently underway.
Thank you for making this simple to understand.
Not only is the Universe stranger than we think, it is stranger than we can think. - Heisenberg - it is releváns for homeopathy too.
Thank you for the research! So hard to explain Homeopathy to new patients. They take it, it works, they come back, want more, still not knowing how it really works! Great stuff. Just gave my puppy a dose of Ledum 200CH after his 2nd booster shots. He stopped trying to nip at the injection site, and fell asleep.
This is a really good summary but I think we focus too much on the hardware of the body and somehow miss its software, the information system of the body. Any plant or animal based medicines has a very complex information mix which is not comparable to metals or other minerals and the body has to be able to "read" these complex info patterns some way or other. So we should start to focus on the software, the information system as well.
I think that homeopathic high potency DO transform our inner software. I see this almost every day of my practice.
The Voll Method pinpoints acute homeopathic remedy needs
Sometimes it does...though no method is 100%...and because many acute symptoms are the results of chronic disease, the Voll machine sometimes is not adequately sensitive to such complexities.